HGF-promoted glioma cell migration requires enhanced TGF-β₂. A, LN-229 neo or nter-ezrin cells were untreated or exposed to HGF (10 ng/ml) for 24 hr and analyzed for TGF-β₂ release as in Figure4A. B, LN-229 and U87MG cells were treated with HGF (10 ng/ml for 24 hr) or TGF-β₂ antibody as in Figure 4B, as indicated, and assessed for migration (mean and SEM; n = 3; ttest; *p < 0.05 for the effect of HGF;^#p < 0.05 for the effect of TGF-β₂ antibody compared with control antibody-treated cells; ⁺p < 0.05 for the effect of TGF-β₂ antibody plus HGF compared with HGF alone).C, The cells were untreated or treated with TGF-β₂ (2 ng/ml) or HGF (10 ng/ml) and assessed for colony formation as in Figure 1C (mean and SEM;n = 3; t test; *p < 0.05; **p < 0.01 for the effect of dominant-negative ezrin; ⁺⁺p< 0.01 for the effect of TGF-β₂ compared with nontreated isogenic cells).